文献速递耳科与耳神经

鼓室内地塞米松预防顺铂诱导耳鸣的随机对照IIIB期临床试验

Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial.
PubMed 文献 · Ear Hear · 2026-04-06

该随机对照IIIB期试验纳入接受顺铂化疗的肿瘤患者,采用鼓室内地塞米松给药(Microwick装置,8 mg/24 h),以同侧耳为对照并设未治疗对照组。结果显示治疗耳无耳鸣报告,而未用地塞米松者90%出现双侧耳鸣,但感染和永久性穿孔并发症值得关注。

要点

  • 鼓室内地塞米松可预防顺铂化疗患者的耳鸣发生。
  • 未治疗患者90%出现双侧耳鸣,THI平均恶化20.2分。
  • 治疗相关感染并发症8.69%,6个月永久性穿孔34.8%。

核心结论

  • 鼓室内长期给予高剂量地塞米松可预防顺铂诱导的耳鸣,且不影响听阈。

研究设计与样本

  • 随机对照IIIB期临床试验,招募34例接受顺铂化疗的肿瘤患者,排除11例。
  • 每例患者随机选择一耳接受地塞米松(Microwick,8 mg/24 h),对侧耳为对照。

主要发现

  • 平均顺铂剂量为444.87 mg(SD: 235.2 mg)。
  • 治疗后治疗耳无患者报告耳鸣。
  • 未接受地塞米松的患者中90%出现双侧耳鸣,耳鸣残疾量表平均恶化20.2分。
  • 地塞米松治疗期间感染并发症发生率为8.69%,装置移除后6个月永久性穿孔率为34.8%。

临床怎么用

  • 对于接受顺铂化疗的患者,可考虑鼓室内地塞米松预防耳鸣,但需权衡感染和穿孔风险。

局限性

  • 原文未报告随机分组细节、盲法及统计学比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cisplatin is a widely used chemotherapy agent. However, one of the side effects associated with cisplatin use is ototoxicity, causing hearing loss, tinnitus, and balance disorders. Furthermore, no preventive treatment for these conditions is currently available. Intratympanic administration of dexamethasone has reduced cisplatin-induced ototoxicity in vivo. However, clinical trials still need to be conducted to assess its efficacy in humans. The aim of this study was to assess the efficacy of intratympanic administration of dexamethasone in preventing tinnitus in patients with cancer undergoing cisplatin-based chemotherapy. DESIGN: We conducted a randomized, controlled, phase IIIB clinical trial. In this trial, we included patients with a neoplastic disease whose treatment protocol comprised cisplatin. During the 2-year study period, we recruited 34 patients at a reference tertiary hospital, of whom 11 were excluded. The treatment consisted of intratympanic administration of dexamethasone using a passive diffusion device called Microwick (8 mg/24 h dose). The dexamethasone administration started concurrently with cisplatin treatment and lasted three weeks after the last chemotherapy cycle. We used a computer system to randomly select one ear of each patient to administer the medication, whereas we used the contralateral ear as the control. In addition, we established another control group consisting of patients not treated with dexamethasone in either ear. Ten patients comprised the untreated control group. We evaluated the tinnitus using the Tinnitus Handicap Inventory at the disease onset and at the end of cisplatin treatment. RESULTS: The average dose of cisplatin was 444.87 mg (SD: 235.2 mg). We analyzed 46 ears of the experimental group (23 treated and 23 untreated) and 20 in the control group. After the treatment, no patient reported tinnitus in either ear. However, bilateral tinnitus was observed in 90% of patients who were not administered dexamethasone, with a mean worsening of 20.2 points on the Tinnitus Handicap Inventory. We observed 8.69% infection complications during dexamethasone treatment and 34.8% permanent perforation at 6 months after device removal. CONCLUSIONS: Intratympanic administration of a high dose of dexamethasone over an extended duration prevents cisplatin-induced tinnitus without affecting the hearing threshold.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Moreno I, Belinchon A. Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial. Ear Hear. 2026. PMID: 41940636. doi:10.1097/AUD.0000000000001818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。